RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases

Figure 4 Establishment of anti-RANKL-injected osteopetrosis model. A: Time course of the effect of anti-mouse receptor activator of nuclear factor-κB ligand (RANKL) neutralizing antibody (clone, OYC1) on bone mass (day 0-28). OYC1 (5 mg/kg) was administered subcutaneously to 6-wk-old female mice (n = 5 or 6) on day 0. Mice were sacrificed on day 0, 1, 2, 3, 4, 7, 14, and 28. Bone structure in the trabecular area was analyzed by micro computer tomography; B: Serum TRAP-5b levels were measured by ELISA. Data are shown as the mean ± SD. ^bP < 0.01 (ANOVA) vs value on day 0.